|
|
|
|
| LEADER |
02724nam a2200289 u 4500 |
| 001 |
EB002001768 |
| 003 |
EBX01000000000000001164669 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Ip, Stanley
|
| 245 |
0 |
0 |
|a Comparative effectiveness of radiofrequency catheter ablation for atrial fibrillation
|h Elektronische Ressource
|c prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Tufts Medical Center Evidence-based Practice Center ; investigators, Stanley Ip ... [et al.]
|
| 260 |
|
|
|a [Rockville, MD
|b Agency for Healthcare Research and Quality
|c 2009], 2009
|
| 300 |
|
|
|a 1 PDF file (1 v. (various pagings
|b ill.)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Comparative Effectiveness Research
|
| 653 |
|
|
|a Catheter Ablation
|
| 653 |
|
|
|a Atrial Fibrillation / radiotherapy
|
| 710 |
2 |
|
|a United States
|b Agency for Healthcare Research and Quality
|
| 710 |
2 |
|
|a Tufts Evidence-based Practice Center
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Comparative effectiveness review
|
| 500 |
|
|
|a Title from PDF t.p. (viewed Aug. 29, 2011). - "July 2009.". - "Contract no. 290-02-0022."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK43190
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The Agency for Healthcare Research and Quality (AHRQ) commissioned this report to review the evidence for the clinical effects and safety of radiofrequency catheter ablation (RFA) for the management of atrial fibrillation (AF). Over the past decade, RFA has rapidly evolved as a tool for managing AF in select patients. This rapid evolution has been driven by an enhanced understanding of the triggers and etiology of AF and the development of advanced catheter and imaging technologies. After extensive discussion with AHRQ and the technical expert panel (TEP), the key questions to be addressed in this report are: 1) What is the effect of RFA on short- (6 to 12 months) and long- (>12 months) term rhythm control, rates of congestive heart failure, left atrial and ventricular size changes, rates of stroke, quality of life, avoiding anticoagulation, and readmissions for persistent, paroxysmal and long-standing persistent (chronic) atrial fibrillation? 2) What are the patient-level and intervention-level characteristics associated with RFA effect on short- and long-term rhythm control? 3) How does the effect of RFA on short- and long-term rhythm control differ among the various techniques or approaches used? 4) What are the short- and long-term complications and harms associated with RFA?
|